2022年11月28日

路加免疫疗法和药物开发中心主任匹兹堡医疗中心大学的希尔曼癌症中心。总经理迈克尔Barbella Editor11.28.22 physIQ已任命杰森·卢克,医学博士FACP,公司的医学顾问委员会。在这个角色中,卢克将提供专家的医疗顾问physIQ助手在肿瘤治疗的持续发展的解决方案,包括physIQ数字为炎症生物标记的发展。”博士。卢克带来广泛immuno-oncology专长physIQ提供不可估量的洞察我们的工作在炎症和肿瘤治疗,“physIQ首席医疗官史蒂夫•Steinhubl医学博士说。“执业医师和研究人员,他将视野,经验,和同理心,我们在physIQ拥抱。physIQ“路加的第一个项目是作为主要研究者在临床研究设计来展示公司的炎症多元变化指数(儿童疾病综合管理)可以使CAR-T,一个突破性的肿瘤治疗,更安全,更容易通过启用实时家庭安全监测CAR-T剂量。路加免疫疗法和药物开发中心主任匹兹堡医疗中心大学的希尔曼癌症中心和匹兹堡大学的副教授。他关注转化治疗immuno-oncology的进步,早期药物开发先进的实体肿瘤和皮肤的恶性血液病患者的管理。在黑素瘤,卢克已经设计并带领两个治疗进展研究记录的角色组合anti-PD1 +低剂量anti-CTLA4 Ab PD1难治性疾病,以及建立角色,和美国食品和药物管理局/ EMA批准佐剂anti-PD1 IIB阶段/ C黑色素瘤。 More generally, Luke has been a lead investigator for clinical trials of many novel immunotherapies in advanced solid tumors. He has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy. Luke’s translational research laboratory focuses on biomedical and bioinformatic approaches to advance cancer immunotherapy. He is an at-large member of the Society for Immunotherapy of Cancer Board of Directors and has held leadership roles in SMR, American Association for Cancer Rresearch, and American Society of Clinical Oncology. Luke is the PI or project leader for multiple funding mechanisms including R01, UM1, P50 and multiple state or private grants. Luke earned his medical degree from Rosalind Franklin University of Medicine and Science/Chicago Medical School in North Chicago. He completed an internship and residency in internal medicine at Boston University Medical Center and fellowships in medicine and medical oncology at Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. physIQ delivers personalized medical predictions that vastly improve patient outcomes. By combining proprietary AI and any wearable biosensor to continuously monitor patients in real-world settings, physIQ advances medicine and enables clinical trial sponsors and clinicians to proactively detect physiological decompensations, improve the safety and efficacy of new therapies and speed time to market, and deliver personalized clinical interventions to improve patient outcomes. Trending